[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Market For Organ Preservation Solutions (By Solutions - Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and Others, and By Preservation Techniques-Hypothermic Perfusion Preservation, Static Cold Storage and Others) - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2016 - 2023

January 2016 | 80 pages | ID: G578DCDD2A2EN
Market Research Engine

US$ 4,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Organ preservation solutions are utilized to safeguard organs before transplantation strategy as these organs in outside atmosphere are powerless furthermore ended up broken once taken out from the human body. To save and keep up organs usefulness for their further use, forexample, transplantation and research, organ conservation arrangements areutilized. Expanding interest for organ transplantation strategies over theglobe is relied upon to drive the development of Organ preservation solutions.What's more, maturing populace will likewise push the development of Organpreservation solutions market as the danger of organ disappointment in elderlyindividuals expands that enlarges the interest for organ transplants. In likemanner, improvement of mechanically propelled answers for saving organs willadvance complement the development of Organ preservation solutions market.

This report contemplates the global Organpreservation solutions market in view of the different arrangements accessiblein the business sector in which organs are saved. These arrangementsincorporate Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor,HBS Solution, siRNA Transplant Solution and others (Ross-Marshall CitrateSolutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto,TranSend, HetaFreeze, MaPersol and CryoStor). The business sector for thesearrangements has been widely examined taking into account number of organtransplant, effectiveness and application zone. The business sector estimateand gauge as far as USD million for every item sort has been accommodated theperiod 2016 to 2023, considering 2015 as the base year. The report additionallygives the exacerbated yearly development rate (% CAGR) for the gauge period2016 to 2023 for every portion.

In light of the sort of conservationsystems used to protect organs, market has been divided as hypothermicperfusion safeguarding (HPP), static icy stockpiling (SCS) and others (thatincorporate normothermic safeguarding and oxygen insufflation procedures). Thebusiness sector for these advancements has been widely broke down in light ofnumber of organ transplant, similarity with arrangement and organs, and cost.The business sector measure and estimate as far as USD million for every itemsort has been accommodated the period 2016 to 2023, considering 2015 as thebase year. The report additionally gives the exacerbated yearly developmentrate (% CAGR) for the gauge period 2016 to 2023 for every portion.

Geographically, the report research worldwidebusiness sector as for four primary districts, specifically, North America,Europe, Asia-Pacific and Rest of the World (RoW). The business sector measureand conjectures as far as income (USD million) for the period 2016 to 2023,considering 2015 as the base year, have been accommodated this portion. Thereport likewise gives the intensified yearly development rate (% CAGR) for theestimate period 2015 to 2023 for every fragment.

The business sector outline area of thereport talks about the business sector progress that incorporate drivers,limitations and opportunities affecting the business sector. Likewise, realoccasions have additionally been talked about in the segment that have helpedthe development of the business sector and anticipated that would facilitatepush the development amid the gauge period. Likewise, this segment coversmarket engaging quality investigation (by topography) for the year 2015 and Porter'sfive strengths study for the global ultrasound gadgets market. Piece of theoverall industry (%) by income for the real players working in this businesssector has additionally been accommodated the year 2015 in the aggressive scenesegment, trailed by a rundown of proposals for the current and new players.What's more, the report likewise profiled key players of the business sector ondifferent parameters, for example, business outline, budgetary diagram, itemportfolio, business procedures and late advancements of the separateorganization. A portion of the unmistakable players in the organ safeguardingarrangements showcase that have been profiled in this report incorporate Dr. FranzKöhler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb,BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc.

The global organ protection arrangementsmarket has been sectioned as underneath:

Organ Preservation Solutions Market, bySolution

Viaspan

Custodiol HTK(Histidine-Tryptophan-Ketoglutarate)

Renograf

Hypothermosol

Perfadex

Lifor

Human bioSystem (HBS) Solution

siRNA Transplant Solutions

Others

Organ Preservation Solutions Market, byPreservation Technique

Hypothermic Perfusion Preservation (HPP)

Static Cold Storage (SCS)

Others

Organ Preservation Solutions Market, byGeography

North America

Europe

Asia-Pacific

Rest of the World (RoW)
CHAPTER 1 INTRODUCTION

1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

CHAPTER 2 EXECUTIVESUMMARY

CHAPTER 3 MARKETOVERVIEW

3.1 Introduction
3.2 Market Drivers
  3.2.1 Aging globalpopulation
    3.2.1.1 Global rate of aging population
  3.2.2 Technological advancements
  3.2.3 Increasing reimbursement scenario
  3.2.4 Increasein per capita healthcare expenditure
3.3 Market Restraints
  3.3.1 Lack oforgan donors
    3.3.1.1 Widening Gap Between Patients Receiving Organ Transplantsand Number of Donors in the U.S. (2005 - 2015)
  3.3.2 Highcost of procedure
3.4 Market Opportunities
  3.4.1Collaboration with research-oriented organizations and medical institutes toensure retention of customer base
3.5 Porter’s Five Force Analysis for the Global Organ Preservation Solutions Market
  3.5.1Bargaining power of suppliers
  3.5.2Bargaining power of buyers
  3.5.3 Threatof substitutes
  3.5.4 Threatof new entrants
  3.5.5Competitive rivalry
3.6 Market Attractiveness Analysis:Global Organ Preservation Solutions Market, by Geography

CHAPTER 4 GLOBAL ORGAN PRESERVATION SOLUTIONS MARKET, BY SOLUTION, 2015 – 2023(USD MILLION)

4.1 Overview
  4.1.1 GlobalOrgan Preservation Solutions Market Revenue, by Solution Type, 2015 – 2023 (USDMillion)
  4.1.2Comparative Analysis: Global Organ Preservation Solutions Market, by SolutionType, 2015 & 2013 (Value %)
4.2 Viaspan
  4.2.1 Global Viaspan Market Revenue, 2015 – 2023 (USD Million)
4.3 Custodiol HTK –(Histidine-Tryptophan-Ketoglutarate) Solution
  4.3.1 GlobalCustodiol Market Revenue, 2015 – 2023 (USD Million)
4.4 Renograf
  4.4.1 Global Renograf Market Revenue, 2015 – 2023 (USD Million)
4.5 Hypothermosol
  4.5.1 GlobalHypothermosol Market Revenue, 2015 – 2023 (USD Million)
4.6 Perfadex
  4.6.1 Global Perfadex Market Revenue, 2015 – 2023 (USD Million)
4.7 Lifor
  4.7.1 Global Lifor Market Revenue, 2015 – 2023 (USD Million)
4.8 Human bio System (HBS) Solution
  4.8.1 Global HBS Solution Market Revenue, 2015 – 2023 (USD Million)
4.9 siRNA Transplant Solution
  4.9.1 Global siRNA Transplant Solution Market Revenue, 2015 – 2023 (USD Million)
4.10 Others
  4.10.1 GlobalOther Solutions Market Revenue, 2015 – 2023 (USD Million)

CHAPTER 5 GLOBAL ORGAN PRESERVATION SOLUTIONS MARKET, BY PRESERVATION TECHNIQUE, 2015 – 2023(USD MILLION)

5.1 Overview
  5.1.1 Global Organ Preservation Solutions Market Revenue, by Preservation Technique, 2015 –2023 (USD Million)
  5.1.2 Comparative Analysis: Global Organ Preservation Solutions Market, by Preservation Technique, 2015 & 2023 (Value %)
5.2 Hypothermic Perfusion Preservation(HPP)
  5.2.1 GlobalHypothermic Perfusion Preservation Market Revenue, 2015 – 2023 (USD Million)
5.3 Static Cold Storage (SCS)
  5.3.1 Global Static Cold Storage Market Revenue, 2015 – 2023 (USD Million)
5.4 Others
  5.4.1 Global Other Preservation Techniques Market Revenue, 2015 – 2023 (USD Million)

CHAPTER 6 GLOBAL ORGAN PRESERVATION SOLUTIONS MARKET, BY GEOGRAPHY, 2015 – 2023(USD MILLION)

6.1 Overview
  6.1.1 Global Organ Preservation Solutions Market Revenue, by Geography, 2015 – 2023 (USDMillion)
  6.1.2Comparative Analysis: Global Organ Preservation Solutions Market, by Geography,2015 & 2023 (Value %)
6.2 North America
  6.2.1 North America Organ Preservation Solutions Market Revenue, 2015 – 2023 (USD Million)
6.3 Europe
  6.3.1 Europe Deceased Donation Rate (Per Million of Population), by Country, 2015
  6.3.2 Europe Organ Donation and Transplantation Data, 2015
  6.3.3 Donation and Transplantation Number Per European Country, 2015
  6.3.4 Europe Organ Preservation Solutions Market Revenue, 2015 – 2023 (USD Million)
6.4 Asia Pacific
  6.4.1 Organ Donation and Transplantation Data for Japan (2010 - 2014)
  6.4.2 Asia Pacific Organ Preservation Solutions Market Revenue, 2015 – 2023 (USD Million)
6.5 Rest of the World (RoW)
  6.5.1 RoW Organ Preservation Solutions Market Revenue, 2015 – 2023 (USD Million)

CHAPTER 7 COMPETITIVE LANDSCAPE

7.1 Market Share by Key Players, 2015(%)

CHAPTER 8 RECOMMENDATIONS

8.1 Long term contracts with healthcare service providers
8.2 Broadening of distribution network
8.3 Product innovation

CHAPTER 9 COMPANYPROFILES

9.1 21st Century Medicine
  9.1.1 Company Overview
  9.1.2 Product Portfolio
9.2 BioLife Solutions, Inc.
  9.2.1 Company Overview
  9.2.2Financial Overview
  9.2.3 Product Portfolio
  9.2.4 Business Strategies
  9.2.5 Recent Developments
9.3 BioTime, Inc.
  9.3.1 CompanyOverview
  9.3.2 Financial Overview
  9.3.3 Product Portfolio
  9.3.4 Business Strategies
  9.3.5 Recent Developments
9.4 Bristol-Myers Squibb
  9.4.1 Company Overview
  9.4.2Financial Overview
  9.4.3 Product Portfolio
  9.4.4 Business Strategies
  9.4.5 Recent Developments
9.5 Claris Life sciences Limited
  9.5.1 Company Overview
  9.5.2Financial Overview
  9.5.3 Product Portfolio
  9.5.4 Business Strategies
  9.5.5 Recent Developments
9.6 CryoLife, Inc.
  9.6.1 Company Overview
  9.6.2Financial Overview
  9.6.3 Product Portfolio
  9.6.4 Business Strategies
  9.6.5 Recent Developments
9.7 Dr. Franz Köhler Chemie GmbH
  9.7.1 Company Overview
  9.7.2 Product Portfolio
  9.7.3 Business Strategies
9.8 Lifeline Scientific
  9.8.1 Company Profile
  9.8.2Financial Overview
  9.8.3 Product Portfolio
  9.8.4 Business Strategies
  9.8.5 Recent Developments
9.9 Teva Pharmaceutical Industries Ltd.
  9.9.1 Company Profile
  9.9.2 Financial Overview
  9.9.3 Product Portfolio
  9.9.4 Business Strategies
  9.9.5 Recent Developments
9.10 ToleroTech, Inc.
  9.10.1 Company Profile
  9.10.2 Product Portfolio
  9.10.3 Business Strategies
9.11 XVIVO Perfusion AB
  9.11.1 CompanyOverview
  9.11.2 Financial Overview
  9.11.3 Product Portfolio
  9.11.4 Business Strategies


More Publications